Status:
COMPLETED
Robotic Versus Open Surgery Following Neoadjuvant Therapy in Pancreatic Cancer: Evaluation of Safety and Oncologic Outcomes
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Pancreatic Cancer
Neoadjuvant Therapy
Eligibility:
All Genders
18+ years
Brief Summary
The feasibility and safety of minimally invasive surgery in cases after neoadjuvant therapy were unclear. It is worth exploring the safety of robotic resection for pancreatic cancer following neoadjuv...
Detailed Description
Currently, most studies focus on upfront resectable pancreatic cancer, benign or low-grade malignant tumors, demonstrating that robotic surgery can shorten postoperative hospital stays, reduce intraop...
Eligibility Criteria
Inclusion
- Age over 18 years.
- Received neoadjuvant chemotherapy.
- Postoperative pathology confirmed pancreatic cancer.
- Underwent either open or robotic surgery.
Exclusion
- Intraoperative discovery of unresectable tumor or presence of distant metastasis.
- ASA score ≥ 4.
Key Trial Info
Start Date :
February 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2025
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT07147374
Start Date
February 1 2017
End Date
July 31 2025
Last Update
August 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of General Surgery, Peking Union Medical College Hospital (PUMCH)
Beijing, Beijing Municipality, China, 100730